Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases

Dongxiao Sun, Arun K. Sharma, Ryan W. Dellinger, Andrea S. Blevins-Primeau, Renee M. Balliet, Gang Chen, Telih Boyiri, Shantu Amin and Philip Lazarus
Drug Metabolism and Disposition November 2007, 35 (11) 2006-2014; DOI: https://doi.org/10.1124/dmd.107.017145
Dongxiao Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arun K. Sharma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan W. Dellinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea S. Blevins-Primeau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renee M. Balliet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Telih Boyiri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shantu Amin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Lazarus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Tamoxifen (TAM) is an antiestrogen that has been widely used in the treatment and prevention of breast cancer in women. One of the major mechanisms of metabolism and elimination of TAM and its major active metabolites 4-hydroxytamoxifen (4-OH-TAM) and 4-OH-N-desmethyl-TAM (endoxifen; 4-hydroxy-N-desmethyl-tamoxifen) is via glucuronidation. Although limited studies have been performed characterizing the glucuronidation of 4-OH-TAM, no studies have been performed on endoxifen. In the present study, characterization of the glucuronidating activities of human UDP glucuronosyltransferases (UGTs) against isomers of 4-OH-TAM and endoxifen was performed. Using homogenates of individual UGT-overexpressing cell lines, UGTs 2B7 ∼ 1A8 > UGT1A10 exhibited the highest overall O-glucuronidating activity against trans-4-OH-TAM as determined by Vmax/KM, with the hepatic enzyme UGT2B7 exhibiting the highest binding affinity and lowest KM (3.7 μM). As determined by Vmax/KM, UGT1A10 exhibited the highest overall O-glucuronidating activity against cis-4-OH-TAM, 10-fold higher than the next-most active UGTs 1A1 and 2B7, but with UGT1A7 exhibiting the lowest KM. Although both N- and O-glucuronidation occurred for 4-OH-TAM in human liver microsomes, only O-glucuronidating activity was observed for endoxifen; no endoxifen-N-glucuronidation was observed for any UGT tested. UGTs 1A10 ∼ 1A8 > UGT2B7 exhibited the highest overall glucuronidating activities as determined by Vmax/KM for trans-endoxifen, with the extrahepatic enzyme UGT1A10 exhibiting the highest binding affinity and lowest KM (39.9 μM). Similar to that observed for cis-4-OH-TAM, UGT1A10 also exhibited the highest activity for cis-endoxifen. These data suggest that several UGTs, including UGTs 1A10, 2B7, and 1A8 play an important role in the metabolism of 4-OH-TAM and endoxifen.

Footnotes

  • This study was supported by U.S. Public Health Service Grant P01-68384 (National Cancer Institute) from the Department of Health and Human Services, National Institutes of Health (to P.L.) and a formula grant under the Pennsylvania Department of Health's Health Research Formula Funding Program (State of Pennsylvania, Act 2001-77, part of the Pennsylvania Tobacco Settlement Legislation) (to P.L.).

  • doi:10.1124/dmd.107.017145.

  • ABBREVIATIONS: TAM, tamoxifen; 4-OH-TAM, 4-hydroxytamoxifen; 4-OH-N-desmethyl-TAM, 4-hydroxy-N-desmethyl-tamoxifen (endoxifen); UGT, UDP-glucuronosyltransferase; UDPGA, UDP-glucuronic acid; DMEM, Dulbecco's modified Eagle's medium; BCA, bicinchoninic acid; PCR, polymerase chain reaction; SDM, site-directed mutagenesis; HEK, human embryonic kidney; LC/MS, liquid chromatography/mass spectrometry; MS, mass spectrometric; HPLC, high-pressure liquid chromatography; DMSO, dimethyl sulfoxide; HLM, human liver microsome; Std, standard.

    • Received June 11, 2007.
    • Accepted July 25, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 35 (11)
Drug Metabolism and Disposition
Vol. 35, Issue 11
1 Nov 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
Citation Tools
Research ArticleArticle

Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases

Dongxiao Sun, Arun K. Sharma, Ryan W. Dellinger, Andrea S. Blevins-Primeau, Renee M. Balliet, Gang Chen, Telih Boyiri, Shantu Amin and Philip Lazarus
Drug Metabolism and Disposition November 1, 2007, 35 (11) 2006-2014; DOI: https://doi.org/10.1124/dmd.107.017145

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases

Dongxiao Sun, Arun K. Sharma, Ryan W. Dellinger, Andrea S. Blevins-Primeau, Renee M. Balliet, Gang Chen, Telih Boyiri, Shantu Amin and Philip Lazarus
Drug Metabolism and Disposition November 1, 2007, 35 (11) 2006-2014; DOI: https://doi.org/10.1124/dmd.107.017145
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Esaxerenone ADME in Humans and In Vitro
  • LncRNAs Regulated by PXR and CAR Agonists in Mouse Liver
  • Segregated Hepatocyte Scaling Factors in Prediction of Clearance
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics